Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Ventyx Biosciences (Nasdaq: VTYX), a clinical-stage biopharmaceutical company specializing in innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.

The virtual event is scheduled for Wednesday, February 12, 2025, from 2:40-3:10 PM ET. The company will provide a presentation, which will be accessible via webcast through the Investors and News section of Ventyx's website at www.ventyxbio.com. A replay of the presentation will remain available on the website for ninety days following the event.

News Market Reaction – VTYX

+0.54%

1 alert

+0.54% News Effect

On the day this news was published, VTYX gained 0.54%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.

• Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference
  Location: Virtual
  Date: Wednesday, February 12, 2025
  Time: 2:40-3:10 PM ET

A webcast of the presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event for ninety days.

About Ventyx Biosciences

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drugs through clinical trials. Our lead portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase 2 development for neurodegenerative and cardiometabolic diseases. Our inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials.

Investor Relations Contact:
Joyce Allaire
Managing Director
LifeSci Advisors
IR@ventyxbio.com

FAQ

When is Ventyx Biosciences (VTYX) presenting at the Oppenheimer Healthcare Conference 2025?

Ventyx Biosciences is scheduled to present at the Oppenheimer Healthcare Conference on Wednesday, February 12, 2025, from 2:40-3:10 PM ET.

How can investors access the VTYX presentation at the Oppenheimer Conference?

Investors can access the presentation webcast through the Investors and News section of Ventyx's website at www.ventyxbio.com.

How long will the VTYX Oppenheimer Conference presentation replay be available?

The webcast replay will be available on Ventyx's website for ninety days after the presentation.

What therapeutic areas does Ventyx Biosciences (VTYX) focus on?

Ventyx Biosciences focuses on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases.